2025 Preeclampsia Drugs Industry Trends Report: Long-Term Outlook Through 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Preeclampsia Drugs Market Size By 2025?
The market size for drugs treating preeclampsia has seen robust growth in recent years. The market is expected to expand from $1.25 billion in 2024 to $1.37 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. The upswing during the historic period has been driven by enhanced awareness regarding maternal health, investment in research and development, concerns regarding neonatal health, and improvements in early detection.

How Big Is the Preeclampsia Drugs Market Size Expected to Grow by 2029?
In the upcoming years, the preeclampsia drugs market is projected to experience a swift expansion. This market is forecasted to reach "$2.1 billion in 2029 with a compound annual growth rate (CAGR) of 11.2%. The market expansion during the predictive period can be credited to factors such as personalized medicine, non-invasive diagnostic instruments, targeted treatments, and health equality initiatives. The primary trends anticipated during this period consist of preventative methodologies, patient-focused care, constant observation, and regulatory concentration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Which Key Market Drivers Powering Preeclampsia Drugs Market Expansion and Growth?
There's an anticipated surge in the preeclampsia drug market due to the prevalence of diabetes among pregnant women. Diabetes, a long-term metabolic disorder, results in elevated blood glucose levels. Preeclampsia, a detrimental condition during pregnancy, is associated with high blood pressure and organ injuries. Metformin, a drug used to treat preeclampsia, is commonly prescribed to pregnant women diagnosed with early preeclampsia. As per the data from the National Library of Medicine, a US-based biomedical library and biomedical informatics center, in December 2022, the number of gestational diabetes mellitus (GDM) cases recorded was 20,865, marking a 6.56% increase compared to the previous year. We can thus, anticipate that the escalating rate of diabetes among pregnant women will push the preeclampsia drug market forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

What Trends Will Shape the Preeclampsia Drugs Market Through 2029 and Beyond?
Leading enterprises in the preeclampsia medicine industry are keen on inventing sophisticated drug therapies to enhance their place in the market. To illustrate, Comanche Biopharma Corp., an American biopharmaceutical company, announced in March 2023 that its novel siRNA treatment, CBP-4888, has received Food and Drug Administration (FDA) approval for an investigational new drug (IND) application for treating preeclampsia. Administered subcutaneously, CBP-4888 is an siRNA therapy that curtails the production of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. Overproduction of the sFLT1 protein by the placenta, which then enters the mother's bloodstream, is primarily responsible for preeclampsia. CBP-4888 is capable of mitigating preeclampsia symptoms, such as elevated blood pressure and harm to organs, potentially facilitating a safe prolongation of pregnancy.

What Are the Emerging Segments in the Preeclampsia Drugs Market?
The preeclampsia drugs market covered in this report is segmented -

1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13025&type=smp

Who Are the Global Leaders in the Preeclampsia Drugs Market?
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.

Which are the Top Profitable Regional Markets for the Preeclampsia Drugs Industry?
North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13025

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.